Mercer Global Advisors
PHAT icon

Mercer Global Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Mercer Global Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
+1,337
New +$15.3K ﹤0.01% 4977

Other funds holding PHAT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Mercer Global Advisors's PHAT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 1,337 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #4977 among its holdings.

104 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Mercer Global Advisors held 1,337 shares of Phathom Pharmaceuticals worth $14.5K as of Q2 2026.
  • Phathom Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4977 holding.
  • 104 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.